NEUROFIND PROLONGED RELEASE TABLETS 36 MG

Laboratorios LICONSA S.A. (SPAIN)🇸🇬 Health Sciences Authority

Approval Date: Jun 5, 2024
Approval ID: e92266779bb2d559
Company: Laboratorios LICONSA S.A. (SPAIN)
Type: Therapeutic

Approval Details

Approval Id: e92266779bb2d559
Drug Name: NEUROFIND PROLONGED RELEASE TABLETS 36 MG
Product Name: NEUROFIND PROLONGED RELEASE TABLETS 36 MG
Approval Number: SIN17023P
Approval Date: 2024-06-05
Registrant: LOTUS INTERNATIONAL PTE. LTD.
Licence Holder: LOTUS INTERNATIONAL PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, FILM COATED, EXTENDED RELEASE
Dosage: 4.2 Posology and method of administration Dosage Patients new to methylphenidate The recommended starting dosage of Neurofind for patients who are not currently taking methylphenidate or stimulants other than methylphenidate is 18 mg once daily for children and adolescents and 18 to 36 mg once daily for adults. Patients currently using methylphenidate The recommended dosage of Neurofind for patients who are currently taking methylphenidate twice daily or three times daily at dosages of 10 to 60 mg/day is provided in Table 1. <img src="/TGIF/Neurofind-Table1_081024.png" alt="Neurofind Dosage Table 1" /> Clinical judgment should be used when selecting the starting dose for patients currently taking methylphenidate in other regimens. Dose titration The dosage should be individualized according to the needs and responses of the patient. Doses may be increased in 18 mg increments at weekly intervals. Daily dosages above 54 mg in children, 72 mg in adolescents have not been studied and are not recommended. Daily dosages above 72 mg in adults are not recommended. A 27mg dosage strength is available for physicians who wish to prescribe between 18 and 36mg dosage. Maintenance/extended treatment There is no body of evidence available from controlled trials to indicate how long the patient with ADHD should be treated with methylphenidate. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physician who elects to use methylphenidate for extended periods in patients with ADHD should periodically re-evaluate the long-term usefulness of the drug for the individual patient with trials off medication to assess the patient’s functioning without pharmacotherapy. Improvement may be sustained when the drug is either temporarily or permanently discontinued. Dose reduction and discontinuation If paradoxical aggravation of symptoms or other adverse events occur, the dosage should be reduced, or, if necessary, the drug should be discontinued. If improvement is not observed after appropriate dosage adjustment over a one- month period, the drug should be discontinued. Administration Neurofind is administered orally once daily. As the effect has been shown to be present 12 hours after dosing, the product should be taken once daily in the morning. Neurofind must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed (see Precautions – Information for Patients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Neurofind may be administered with or without food (see Pharmacokinetic Properties – Food effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Special populations Pediatrics (under 6 years of age) Use of prolonged-release methylphenidate in patients under six years of age has not been studied in controlled trials. Methylphenidate should not be used in patients under six years old. Long-term effects of methylphenidate in children are not yet available. Although a causal relationship has not been established, suppression of growth (ie weight gain and/or height) has been reported with the long-term use of stimulants in children. Therefore, patients requiring long-term therapy should be carefully monitored. Patients who are not growing or gaining weight as expected should have their treatment interrupted. Elderly (over 65 years of age) Prolonged-release methylphenidate should not be used in the elderly. Safety and efficacy have not been established in this age group. Renal insufficiency There is no experience with the use of prolonged-release methylphenidate in patients with renal insufficiency (see Pharmacokinetic Properties – Special populations, Renal insufficiency – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic insufficiency There is no experience with the use of prolonged-release methylphenidate in patients with hepatic insufficiency.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Attention-Deficit/Hyperactivity Disorder (ADHD) Neurofind is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of methylphenidate in the treatment of ADHD was established in controlled trials of children and adolescents aged 6 to 17 and adults aged 18 to 65 who met DSM-IV criteria for ADHD. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, eg, in social, academic, or occupational functioning, and be present in two or more settings, eg, school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive type, at least six of the following symptoms must have persisted for at least 6 months, lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months; fidgeting/squirming; leaving seat; inappropriate running/climbing; difficult with quiet activities; “on the go;” excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the purpose of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Methylphenidate is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of methylphenidate for long-term use, ie, for more than 4 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use methylphenidate for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Dosage and Administration).
Contraindications: 4.3 Contraindications Prolonged-release methylphenidate is contraindicated: <ul> <li>in patients known to be hypersensitive to methylphenidate or other components of the product;</li> <li>in patients with glaucoma;</li> <li>during treatment with monoamine oxidase (MAO) inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase (MAO) inhibitor (hypertensive crisis may result) (see Interactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information);</li> <li>in patients with hyperthyroidism;</li> <li>in patients with severe angina pectoris;</li> <li>in patients with cardiac arrhythmia;</li> <li>in patients with phaeochromocytoma.</li> </ul>
Atc Code: N06BA04
Pharma Manufacturer Name: LOTUS INTERNATIONAL PTE. LTD.

Active Ingredients

Methylphenidate Hydrochloride

36 mg

Methylphenidate Hydrochloride

36 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 5, 2024

Approval ID

e92266779bb2d559

Type

Therapeutic

Back to HSA Approvals